



PRIMARY MYELOFIBROSIS

RMA ID Number	Reference List for RMA393-3 as at August 2021
---------------	---

61725	Abdel-Wahab OI, Levine RL (2009). Primary myelofibrosis update on definition pathogenesis, and treatment. <i>Annu Rev Med</i> , 60: 233-45.
65286	Aksoy M, Erdem S, Dincol G (1975). Two rare complications of chronic benzene poisoning: myeloid metaplasia and paroxysmal nocturnal hemoglobinuria. Report of two cases. <i>Blut</i> , 30(4): 255-60.
65997	Anderson DM, Keith J, Novak PD (Lexicographers) (2012). Polychromophil. <i>Dorland's Illustrated Medical Dictionary</i> , 32nd Edition: 1488. Elsevier Saunders, Philadelphia.
64219	Anderson LA, Duncombe AS, Hughes M, et al (2011). Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. <i>Am J Hematol</i> , 87(2): 175-82.
65279	Anderson RE, Hoshino T, Yamamoto T (1964). Myelofibrosis with myeloid metaplasia in survivors of the atomic bomb in Hiroshima. <i>Ann Intern Med</i> , 60: 1-18.
65890	Antonucci R, Walker R, Herion J (1989). Myelofibrosis and aplastic anemia: first report of the two disorders occurring sequentially in the same person. <i>Am J Med</i> , 86(3): 352-5.
8801	Bausa R, Navarro L, Cortes-Franch I (2017). [Myelofibrosis in a benzene-exposed cleaning worker]. <i>Arch Prev Riesgos Labor</i> , 20(3): 167-9 [Article in Spanish]. [Abstract]
52169	Becker N, Liebermann D, Wesch H, et al (2008). Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study. <i>Eur J Cancer</i> , 44(9): 1259-68.
65288	Bernardini P, Giannandrea F, Voso MT, et al (2005). [Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases] [Article in Italian]. <i>Med Lav</i> , 96(2): 119-25. [Abstract]
65891	Bosch X, Campistol JM, Montoliu J, et al (1988). Myelofibrosis and focal segmental glomerulosclerosis associated with toluene poisoning. <i>Hum Toxicol</i> , 7(4): 357-61.
65287	Cankovic M, Whiteley L, Hawley RC, et al (2009). Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory. <i>Am J Clin Pathol</i> , 132(5): 713-21.
65282	Cervantes F (2011). How I treat splenomegaly in myelofibrosis. <i>Blood Cancer J</i> , 1(10): e37.
20013	Chattopadhyay S, Zheng G, Sud A, et al (2018). Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. <i>Lancet Haematol</i> , 5(8): e368-77.
65280	Chin-Yee I, Porter AT, Lohmann RC (1990). Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma. <i>Clin Oncol (R Coll Radiol)</i> , 3(5): 288-90.

31373	Christensen SF, Scherber RM, Brochmann N, et al (2020). Body mass index and total symptom burden in myeloproliferative neoplasms discovery of a U-shaped association. <i>Cancers (Basel)</i> , 12(8): 2202.
38765	Descatha A, Jenabian A, Conso F, et al (2005). Occupational exposures and haematological malignancies: overview on human recent data. <i>Cancer Causes Control</i> , 16(8): 939-53.
43677	dos Santos Silva I, Malveiro F, Jones ME, et al (2003). Mortality after radiological investigation with radioactive Thorotrast: a follow-up study of up to fifty years in Portugal. <i>Radiat Res</i> , 159(4): 521-34.
64320	Dotti G, Savoldo B (2010). [Comment] Response: To force the expression of CCR4 and/or CCR5 chemokine receptor in T cells for immunotherapy of Hodgkin lymphoma: that is the question. <i>Blood</i> , 115(3): 748. Comment on ID: 64269.
8827	Duncombe AS, Anderson LA, James G, et al (2020). Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. <i>Hemasphere</i> , 4(1): e327.
34564	El-Zaemey S, Schinasi LH, Ferro G, et al (2019). Animal farming and the risk of lymphohaematopoietic cancers: a meta-analysis of three cohort studies within the AGRICOH consortium. <i>Occup Environ Health</i> , 76(11): 827-37.
65996	Faderl S, Kantarjian HM (2010). Chronic myeloid leukemia and other myeloproliferative neoplasms. Retrieved 6 December 2012, from www.acpmedicine.com/acpmedicine/institutional/regGetFile.action?fileName=1190.pdf
61721	Fadilah SA, Cheong SK (1999). [Comment] Myelofibrosis following pelvic irradiation for cervical carcinoma. <i>Int J Hematol</i> , 69: 268-9.
65291	Falcetta R, Sacerdote C, Bazzan M, et al (2003). [Occupational and environmental risk factors for essential thrombocythemia: a case-control study]. <i>G Ital Med Lav Ergon</i> , 25(Suppl 3): 9-12 [Article in Italian]. [Abstract]
14205	Faramawi MF, Ndetan H, Jadhav S, et al (2015). A cohort mortality study of workers in a second soup manufacturing plant. <i>Arch Environ Occup Health</i> , 70(5): 279-85.
65294	Fedoriw G, Dunphy CH (2011). Pathology of therapy-related myeloid neoplasms. Retrieved 23 October 2012, from http://emedicine.medscape.com/article/2026238-overview
64371	Ferguson LR, Han DY, Fraser AG, et al (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. <i>Mutat Res</i> , 690(1-2): 108-15.
64217	Fischer M, Helper DJ, Chiorean MV (2011). Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF- α therapy: report of two cases and review of the literature. <i>Inflamm Bowel Dis</i> , 17(2): 674-5.
14245	Garmezzy B, Schaefer JK, Mercer J, et al (2021). A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. <i>Blood Rev</i> , 45: 100691.
71351	Glass DC, Schnatter AR, Tang G, et al (2014). Risk of myeloproliferative disease and chronic myeloid leukemia following exposure to low-level benzene in a nested case-control study of petroleum workers. <i>Occup Environ Med</i> , 71(4): 266-74.
85806	Glass DC, Schnatter AR, Tang G, et al (2017). Exposure to benzene in a pooled analysis of petroleum industry case-control studies. <i>J Occup Environ Hyg</i> , 14(11): 863-72.
65544	Gluzman D, Imamura N, Sklyarenko L, et al (2006). Patterns of hematological malignancies in Chernobyl clean-up workers (1996-2005). <i>Exp Oncol</i> , 28(1): 60-3.

65281	Graham P (1992). [Comment] Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma. <i>Clin Oncol (R Coll Radiol)</i> , 4(3): 203. Comment on ID: 65280.
61606	Greil R, Pleyer L, Neureiter D, et al (2010). Chronic myeloid neoplasias and clonal overlap syndromes. <i>Epidemiology, Pathophysiology and Treatment Options</i> : 1-116. Springer Wien, New York.
17725	Gross SA, Paustenbach DJ (2018). Shanghai Health Study (2001-2009): What was learned about benzene health effects? <i>Crit Rev Toxicol</i> , 48(3): 217-51.
72440	Guidotti TL (2014). Health Risks and Occupation as a Firefighter. Medical Advisory Services, Department of Veterans' Affairs, Commonwealth of Australia.
61720	Harrison C (2010). Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. <i>Hematology Am Soc Hematol Educ Program</i> : 129-33.
64271	Hasselbalch HC (2009). Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer: time to change our therapeutic attitude with early upfront treatment? <i>Leuk Res</i> , 33(1): 11-8.
64268	Hasselbalch HC (2012). Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? <i>Blood</i> , 119(14): 3219-25.
16961	Hayes RB, Blair A, Stewart PA, et al (1990). Mortality of U.S. embalmers and funeral directors. <i>Am J Ind Med</i> , 18(6): 641-52.
26594	Hayes RB, Songnian Y, Dosemeci M, et al (2001). Benzene and lymphohematopoietic malignancies in humans. <i>Am J Ind Med</i> , 40(2): 117-26.
26199	Hayes RB, Yin SN, Dosemeci M, et al (1997). Benzene and dose-related incidence of hematologic neoplasms in China. <i>J Natl Cancer Inst</i> , 89(14): 1065-71.
14170	Heavner K, Gross-Davis CA, Frank AL, et al (2015). Working environment and myeloproliferative neoplasm: A population-based case-control study following a cluster investigation. <i>Am J Ind Med</i> , 58(6): 595-604.
65284	Hu H (1987). Benzene-associated myelofibrosis. <i>Ann Intern Med</i> , 106(1): 171-2.
71192	IARC Working Group (2012). Radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 100D. International Agency for Research on Cancer, Lyon France.
91051	IARC Working Group (2018). Benzene. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 120. World Health Organization, International Agency for Research on Cancer, Lyon France.
66481	Institute of Medicine (2012). Cancer. Veterans and Agent Orange Update: 2010: 499-515. The National Academic Press, Washington DC.
65995	Institute of Medicine (2012). Leukemia. Veterans and Agent Orange Update: 2010. The National Academic Press, Washington DC.
65994	Institute of Medicine (2012). Table 7-15. Veterans and Agent Orange Update: 2010: 354-6. Washington, D.C. National Academy Press.
8793	Jabagi MJ, Vey N, Goncalves A, et al (2019). Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France. <i>JAMA Netw Open</i> , 2(1): e187147.

3686	Jayasuriya NA, Kjaergaard AD, Pedersen KM, et al (2020). Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. <i>Br J Haematol</i> , 189(2): 323-34.
65285	Johnson ES, Zhou Y, Yau CL, et al (2010). Mortality from malignant diseases-update of the Baltimore union poultry cohort. <i>Cancer Causes Control</i> , 21(2): 215-21.
64227	Jones AV, Cross NC (2010). [Comment] No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166. <i>Haematologica</i> , 95(7): 1226-7. Comment on ID: 64226.
64370	Koren-Michowitz M, Landman J, Cohen Y, et al (2012). JAK2V617F allele burden is associated with transformation to myelofibrosis. <i>Leuk Lymphoma</i> , 53(11): 2210-3.
65293	Krishnan K, Besa EC (2012). Secondary thrombocytosis clinical presentation. Retrieved 23 October 2012, from http://emedicine.medscape.com/article/206811-clinicalpresentation
65292	Krishnan K, Besa EC (2012). Secondary thrombocytosis. Retrieved 23 October 2012, from http://emedicine.medscape.com/article/206811-overview
64226	Kristinsson SY, Landgren O, Samuelsson J, et al (2010). Autoimmunity and the risk of myeloproliferative neoplasms. <i>Haematologica</i> , 95(7): 1216-20.
69746	Kroll ME, Murphy F, Pirie K, et al (2012). Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. <i>Br J Cancer</i> , 107(5): 879-87.
66473	Lal A (2012). Agnogenic myeloid metaplasia with myelofibrosis. Retrieved 4 February 2013, from http://emedicine.medscape.com/article/197954-overview
66474	Lal A (2012). Essential thrombocytosis. Retrieved 4 February 2013, from http://emedicine.medscape.com/article/200697-overview
64319	Landgren O, Goldin LR, Kristinsson SY, et al (2008). Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. <i>Blood</i> , 112(6): 2199-204.
8765	Leal AD, Thompson CA, Wang AH, et al (2016). Hormonal and reproductive factors and risk of myeloproliferative neoplasms in postmenopausal women. <i>Cancer Epidemiol Biomarkers Prev</i> , 25(1): 151-7.
8759	Leiba A, Duek A, Afek A, et al (2017). Obesity and related risk of myeloproliferative neoplasms among Israeli adolescents. <i>Obesity (Silver Springs)</i> , 25(7): 1187-90.
8760	Liel AD, Thompson CA, Wang AH, et al (2014). Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. <i>Int J Cancer</i> , 134(7): 1741-50.
56109	Little MP (2009). Cancer and non-cancer effects in Japanese atomic bomb survivors. <i>J Radiol Prot</i> , 29(2A): A43-59.
45580	Lowenthal RM, Tuck DM, Bray IC (2007). Residential exposure to electric power transmission lines and risk of lymphoproliferative and myeloproliferative disorders: a case-control study. <i>Intern Med J</i> , 37(9): 614-9.
65892	Maciel JF, de Lourdes Chauffaille M, Inaoka RJ, et al (2007). [Comment] Essential thrombocythemia after treatment of non-Hodgkin's lymphoma. <i>Leuk Res</i> , 31(11): 1593-5.
75051	Mayo Clinic (2014). Myelofibrosis: risk factors. Retrieved 2 June 2015, from http://www.mayoclinic.org/diseases-conditions/myelofibrosis/basics/risk-factors/con-20027210

14267	McMullin MF, Anderson LA (2020). Aetiology of myeloproliferative neoplasms. <i>Cancers (Basel)</i> , 12(7): 1810.
65290	Mele A, Visani G, Pulsoni A, et al (1996). Risk factors for essential thrombocythemia: A case-control study. Italian Leukemia Study Group. <i>Cancer</i> , 77(10): 2157-61.
3716	Mendez Luque LF, Blackmon AL, Ramanathan G, et al (2019). Key role of inflammation in myeloproliferative neoplasms: Instigator of disease initiation, progression. and symptoms. <i>Curr Hematol Malig Rep</i> , 14(3): 145-53.
65545	Michiels JJ, Juvonen E (1997). Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. <i>Semin Thromb Hemost</i> , 23(4): 339-47.
61722	Miller TD, Farquharson MH (2010). Essential thrombocythaemia and its neurological complications. <i>Pract Neurol</i> , 10(4): 195-201.
72652	Murphy F, Kroll ME, Pirie K, et al (2013). Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. <i>Br J Cancer</i> , 108(11): 2390-8.
61723	Najean Y, Raine JD, Dresch C, et al (1996). Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". <i>Leuk Lymphoma</i> , 22(Suppl 1): 111-9.
90277	National Academies of Sciences, Engineering, and Medicine (2018). <i>Veterans and Agent Orange: Update 11</i> . National Academy Press, Washington D.C.
71803	National Industrial Chemicals Notification and Assessment Scheme (NICNAS) (2001). <i>Benzene: Priority Existing Chemical Assessment Report No. 21</i> . Commonwealth of Australia.
15697	Niazi GA, Fleming AF (1997). Re: benzene and dose-related incidence of hematologic neoplasms in China. <i>J Natl Cancer Inst</i> , 89(22): 1728-9.
64374	Oh ST, Gotlib J (2010). JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. <i>Expert Rev Hematol</i> , 3(3): 323-37.
91038	Pedersen KM, Bak M, Sorensen AL, et al (2018). Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. <i>Cancer Med</i> , 7(11): 5796-802.
14169	Podoltsev NA, Wang X, Wang R, et al (2020). Diet and risk of myeloproliferative neoplasms in older individuals from the NIH-AARP cohort. <i>Cancer Epidemiol Biomarkers Prev</i> , 29(11): 2343-50.
34707	Podoltsev NA, Wang X, Wang R, et al (2020). Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. <i>Int J Cancer</i> , 147(4): 948-57.
8790	Poluben L, Puligandla M, Neuberg D, et al (2019). Genomic characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. <i>Am J Hematol</i> , 94(1): 62-73.
66480	Prchal JT (2012). Primary myelofibrosis. Retrieved 4 February 2013, from http://merckmanuals.com/professional/hematology_oncology/myeloproliferative_disorders/primary_myelofibrosis.html
65993	Prchal JT, Samuelson S (2009). Essential thrombocythemia: Myeloproliferative disorders: Merck manual professional. Retrieved 6 December 2012, from http://merckmanuals.com/professional/hematology_and_oncology/myeloproliferative_disorders/essential_thrombocythemia.html#v974136

31087	Ramanathan G, Hoover BM, Fleischman AG (2020). Impact of host, lifestyle and environmental factors in the pathogenesis of MPN. <i>Cancers (Basel)</i> , 12(8): 2038.
61595	Reilly JT (2006). Idiopathic myelofibrosis: pathogenesis to treatment. <i>Hematol Oncol</i> , 24(2): 56-63.
26595	Robbins A (2001). [Comment] Re: Benzene and lymphohematopoietic malignancies in humans. <i>Am J Ind Med</i> , 40(6): 714-6.
61724	Rumi E, Elena C, Passamonti F (2010). Mutational status of myeloproliferative neoplasms. <i>Crit Rev Eukaryot Gene Expr</i> , 20(1): 61-76.
64223	Rumi E, Harutyunyan A, Elena C, et al (2011). Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. <i>Am J Hematol</i> , 86(12): 974-9.
61593	Santos FP, Verstovsek S (2011). JAK2 inhibitors: what's the true therapeutic potential? <i>Blood Rev</i> , 25(2): 53-63.
8792	Shallis RM, Wang R, Davidoff A, et al (2020). Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Rev</i> , 42: 100706.
14164	Spivak JL (2018). Polycythemia vera and other myeloproliferative neoplasms. <i>Harrison's Principles of Internal Medicine</i> , 20th Edition, Chapter 99. McGraw-Hill.
61592	Stein BL, Moliterno AR (2010). Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. <i>JAMA</i> , 303(24): 2513-8.
64225	Stuart BJ, Viera AJ (2004). Polycythemia vera. <i>Am Fam Physician</i> , 69(9): 2139-44.
64224	Sulai NH, Tefferi A (2012). Why does my patient have thrombocytosis? <i>Hematol Oncol Clin North Am</i> , 26(2): 285-301.
61596	Tefferi A (2010). Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. <i>Leukemia</i> , 24(6): 1128-38.
64216	Tefferi A (2012). Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. <i>Am J Hematol</i> , 87(3): 285-93.
8758	Tefferi A (2020). Clinical manifestations and diagnosis of primary myelofibrosis. Retrieved 27 January 2021, from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-primary-myelofibrosis
96890	Tefferi A (2020). Management of primary myelofibrosis. Retrieved 15 February 2021, from https://www.uptodate.com/contents/management-of-primary-myelofibrosis
5907	Tefferi A (2020). Pathogenetic mechanisms in primary myelofibrosis. Retrieved 27 January 2021, from https://www.uptodate.com/contents/pathogenetic-mechanisms-in-primary-myelofibrosis
61594	Tefferi A, Vainchenker W (2011). Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. <i>J Clin Oncol</i> , 29(5): 573-82.
65283	Thiele J, Kvasnicka HM (2007). Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading. <i>Pathobiology</i> , 74(2): 89-96.
75052	Tondel M, Persson B, Carstensen J (1995). Myelofibrosis and benzene exposure. <i>Occup Med</i> , 45(1): 51-2.
35941	Travis LB, Hauptmann M, Gaul LK, et al (2003). Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorocontrast. <i>Radiat Res</i> , 160(6): 691-706.

75049	U.S. Department of Health & Human Services (2007). Toxicological profile for benzene. Retrieved 2 June 2015, from http://www.atsdr.cdc.gov/toxprofiles/tp3.pdf
64478	United Nations Scientific Committee on the Effects of Atomic Radiation (2008). Sources and effects of ionizing radiation. UNSCEAR 2008 Report to the General Assembly with Scientific Annexes, Vol II Annex D: 151-89. United Nations, New York.
60230	UNSCEAR (2008). Effects of Ionizing Radiation. UNSCEAR 2006 Report. United Nations Scientific Committee on the Effects of Atomic Radiation, Volume 1: 101. United Nations Publication.
75050	US Environmental Department (1976). Health effects of benzene: a review. Retrieved 2 June 2015, from http://nepis.epa.gov/Exe/ZyNET.exe/91012G0L.TXT?ZyActionD=ZyDocument&Client=EPA&Index=1976+Thru+1980&Docs=&Query=&Time=&EndTime=&SearchMethod=1&TocRestrict=n&Toc=&TocEntry=&QField=&QFieldYear=&QFieldMonth=&QFieldDay=&IntQFieldOp=0&ExtQFieldOp=0&XmlQuery=&File=D%3A%5Czyfiles%5CIndex%20Data%5C76thru80%5Ctxt%5C00000022%5C91012G0L.txt&User=ANONYMOUS&Password=anonymous&SortMethod=h%7C-&MaximumDocuments=1&FuzzyDegree=0&ImageQuality=r75g8/r75g8/x150y150g16/i425&Display=p%7Cf&DefSeekPage=x&SearchBack=ZyActionL&Back=ZyActionS&BackDesc=Results%20page&MaximumPages=1&ZyEntry=1&SeekPage=x&ZyPURL
64373	Vainchenker W, Delhommeau F, Constantinescu SN, et al (2011). New mutations and pathogenesis of myeloproliferative neoplasms. <i>Blood</i> , 118(7): 1723-35.
64220	Vannucchi AM, Guglielmelli P (2010). Advances in understanding and management of polycythemia vera. <i>Curr Opin Oncol</i> , 22(6): 636-41.
64372	Vannucchi AM, Guglielmelli P, Tefferi A (2009). Advances in understanding and management of myeloproliferative neoplasms. <i>CA Cancer J Clin</i> , 59(3): 171-91.
64228	Vardiman J, Hyjek E (2011). World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. <i>Hematology Am Soc Hematol Educ Program</i> , 2011: 250-6.
64269	Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. <i>Blood</i> , 114(5): 937-51.
67411	Vassiliou GS, Green AR (2007). Polycythaemia, essential thrombocythaemia and myelofibrosis. <i>ABC of Clinical Haematology</i> , 3rd Edition, Chapter 4: 17-21. Blackwell Publishing.
61607	Verstovsek S, Tefferi A (2011). <i>Myeloproliferative Neoplasms: Biology and Therapy</i> . Humana Press, New York.
1258	Visfeldt J, Andersson M (1995). Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. <i>APMIS</i> , 103(1): 29-36.
64221	Wadleigh M, Tefferi A (2010). Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. <i>Int J Hematol</i> , 91(2): 174-9.
59011	Wakeford R (2009). Radiation in the workplace-a review of studies of the risks of occupational exposure to ionising radiation. <i>J Radiol Prot</i> , 29(2A): A61-79.
65289	Walker AR, Rothberg PG, Liesveld JL (2007). A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML. <i>Bone Marrow Transplant</i> , 39(11): 725-6.
64270	Wandt H, Haferlach T, Thiede C, et al (2010). [Comment] WHO classification of myeloid neoplasms and leukemia. <i>Blood</i> , 115(3): 748-9; author reply: 749-50. Comment on ID: 64269.

64218	Weinberg I, Borohovitz A, Krichevsky S, et al (2011). Janus Kinase V617F mutation in cigarette smokers. <i>Am J Hematol</i> , 87(1): 5-8.
61726	Wolf D, Rudzki J, Gastl G (2011). Current treatment of concepts of Philadelphia-negative MPN. <i>Curr Cancer Drug Targets</i> , 11(1): 44-55.
14490	Wong O (1998). [Comment] Re: benzene and the dose-related incidence of hematologic neoplasms in China. <i>J Natl Cancer Inst</i> , 90(6): 469-71.
64222	Zhang SJ, Abdel-Wahab O (2012). Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. <i>Curr Hematol Malig Rep</i> , 7(1): 34-42.